Enhancing neurogenesis may be a powerful stroke therapy. Here, we tested in a rat model of ischemic stroke the beneficial effects of NSI-189, an orally active, new molecular entity (mol. wt. 366) with enhanced neurogenic activity, and indicated as an anti-depressant drug in a clinical trial (Fava et al., 2015, Molecular Psychiatry, DOI: 10.1038/mp.2015 
several laboratory studies have examined stem cell therapy for treating various diseases in the CNS, including stroke, and neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease (Borlongan, 2011; Borlongan, Glover, Tajiri, Kaneko, & Freeman, 2011) . Stem cell therapy, however, remains as an experimental treatment. While brain injury has been shown to trigger transient and limited neurogenesis, this endogenous protective mechanism is not capable of reversing the cell death cascade in the CNS. It is, however, recognized that strategies designed to enhance the endogenous neurogenesis are potentially beneficial for treating brain disorders Borlongan, 2011; Hess & Borlongan, 2008a; Yasuhara et al., 2006) . Regenerative medicine has emerged as a new scientific field advancing stem cell therapy for treating brain disorders, with emphasis on either transplanting exogenous stem cells or amplifying endogenous stem cells via neurogenesis (Hess & Borlongan, 2008b; Picard-Riera, Nait-Oumesmar, & Baron-Van Evercooren, 2004 ).
The present study focused on the latter one, which incorporates a natural way of protecting, and possibly repairing the damaged brain and correcting the behavioral impairments. In this study, we tested in a stroke model the therapeutic effects of NSI-189, a small molecule with enhanced neurogenic activity, which is already in clinical trial for treatment of major depression and prevention against suicide (ClinicalTrials.gov, 2016; Fava et al., 2015) . While the brain exerts self-repair acutely, over time the stroke-induced cascade of cell death events outweighs the endogenous regenerative mechanisms (Acosta et al., 2013; Fava et al., 2015; Kokaia & Darsalia, 2011; Sun et al., 2013 Sun et al., , 2016 Zhang et al., 2012) . Thus, finding a therapeutic strategy to stimulate the brain to mount a prolonged and stable reparative machinery during the secondary cell death progression after stroke will likely afford beneficial effects. Although NSI-189 has been reported to show neurogenic effects (Fava et al., 2015) , the exact mechanisms mediating this observed neurogenesis remains not well understood. To this end, we posit that a therapeutic approach against stroke may be achieved by rendering the brain to maintain its reparative capacity via enhancement of host neurogenesis that likely entails growth factor upregulation and neurite outgrowth enhancement. The proposed study elucidated the biological effects of orally administered small molecule NSI-189, on promoting neurogenesis, and exerting functional benefits in a stroke model.
| METHODS
This study was designed to evaluate potential therapeutic value of treatment with a novel neurogenic compound, NSI-189. Phosphate, hereafter referred to as NSI-189 (supplied by Neuralstem Inc., Germantown, MD) in an animal model of adult ischemic stroke. A summary of timeline and procedures is provided for clarity of experimental design (Table 1) . Drug treatment was initiated at 6 hr after stroke and daily thereafter for 12 weeks, with functional readouts of behavioral and histological deficits conducted during the subsequent 12-or 24-week period post-treatment. We characterized motor and neurological performance at baseline (prior to stroke), then at 1, 3, and 7 days after stroke and at weekly/monthly intervals thereafter. Following completion of behavioral testing at 12 weeks or 24 weeks post-treatment, animals were randomly euthanized by transcardial perfusion and brains harvested to histologically characterize the extent of cerebral ischemia and to reveal the host tissue endogenous repair mechanism (i.e., neurogenesis). Investigators who were involved in drug treatments, behavioral testing, and post-mortem analyzes were blind to the treatment conditions.
| Stroke surgery
A total of 60 adult Sprague-Dawley, male rats (weighing around 250 g at beginning of the study) received experimental stroke surgery using the middle cerebral artery occlusion (MCAo) model. All surgical procedures will be conducted under aseptic conditions. The animals were anesthetized with 1-2% isoflurane in nitrous oxide/oxygen (69%/30%) using a face mask and checked for pain reflexes. Under deep anesthesia, animals underwent the MCAo surgery. The MCAo suture technique involved insertion of a filament through the carotid artery to reach the junction of the MCA, thus blocking the blood flow from the common carotid artery, as well as from the circle of Willis. The right common carotid artery was identified and isolated through a ventral midline cervical incision. The suture size was 4-0, made of sterile, non-absorbable suture (Ethicon, Inc., Somerville, NJ), with the diameter of the suture tip tapered to 24-26-gauge size using a rubber cement. About 15-17 mm of the filament was inserted from the junction of the external and internal carotid arteries to block the MCA. The right MCA was occluded for 1 hr. A heating pad and a rectal thermometer allowed maintenance of body temperature within normal limits (37 ± 0.3°C). To determine successful occlusion and reperfusion, a laser Doppler probe was placed at the distal end of the MCA and revealed at least 80% reduction in regional cerebral blood flow.
To further ensure similar degree of stroke insults, physiological parameters including PaO 2 , PaCO 2 , and plasma pH measurements were monitored, and we found no significant differences in our stroke animals. Based on laser Doppler readouts and behavioral tests after MCAs, a total of 48 animals were enrolled in this study.
| Drug treatment
All drug treatments were conducted under aseptic conditions. Test article was NSI-189 H 3 PO 4 (mol. wt. 464.50), with lot number DAJ-F-40(2). Purity was 99.8% and stability was determined as stable were randomly assigned to receive oral NSI-189 (n = 24) or vehicle (n = 24), starting at 6 hr after stroke, and daily for the next 12 weeks.
| Motor and neurological tests
All investigators testing the animals were blinded to the treatment condition. Animals will be subjected to elevated body swing test retesting. These steps were repeated 20 times for each animal. About 1 hr after the EBST, the neurological exam was conducted. Neurologic score for each rat was obtained using three tests which include (1) forelimb retraction, which measured the ability of the animal to replace the forelimb after it was displaced laterally by 2-3 cm, graded from 0 (immediate replacement) to 3 (replacement after several seconds or no replacement); (2) beam walking ability, graded 0 for a rat that readily traversed a 2.4-cm-wide, 80-cm-long beam to 3 for a rat unable to stay on the beam for 10 s; and (3) bilateral forepaw grasp, which measured the ability to hold onto a 2-mm-diameter steel rod, graded 0 for a rat with normal forepaw grasping behavior to 3 for a rat unable to grasp with the forepaws. The scores from all three tests, which were done over a period of about 15 min on each assessment day, were added to give a mean neurologic deficit score (maximum possible score, 9 points divided by 3 tests = 3). Animals were subjected to both tests at baseline (prior to stroke), then at 1, 3, 7 days after stroke and at weekly intervals post-treatment.
| Histology
All post-mortem histology was performed by Neurodigitech. At (Fig. 2) . In contrast, examination of secondary cell death in the peri-infarct cortex revealed apparent upregulation of cell proliferation and neurogenesis as evidenced by increased Ki67 (Fig. 2) and MAP2 (Fig. 3) staining, respectively, in NSI-189-treated stroke animals compared to vehicletreated stroke animals. NSI-189-treated stroke animals displayed significant increments in MAP2 density compared to vehicle-treated stroke animals, which were more pronounced in the hippocampus than the cortex, in that the amplified MAP2 density in the cerebral cortex was only detected at the 12-week period, whereas such increased MAP2 density was found in the hippocampus for both 12-and 24-week time points (p's < 0.05). Altogether, these data suggest an active remodeling of the stroke brain, characterized by cell proliferation and neuronal maturation preferentially in the cortex and hippocampal areas, respectively, undergoing secondary cell death as opposed to the striatal areas proximal to the primary stroke insulted region.
| NSI-189 upregulates neurogenic factors in tandem with neurogenesis
In an effort to understand the mechanism of action mediating the observed in vivo therapeutic effects of NSI-189 in stroke, we conducted in vitro studies in order to further probe this remodeling process and demonstrated that oxygen glucose deprivation (OGD) initiated typical cell death processes accompanied by minimum Ki67 expression and decreased MAP2 expression, which were reversed by NSI-189 treatment characterized by significant attenuation of OGD-mediated hippocampal cell death and increased Ki67 and MAP2 expression (p's < 0.05) (Fig. 4) . ELISA demonstrated that VEGF, GDNF, BDNF, and SCF levels were upregulated in the CM of NSI-treated hippocampal cells compared to standard growth media (p's < 0.05), with BDNF and SCF much more robustly increased than VEGF and GDNF (p's < 0.05). Antibody blocking treatments with combined antibody-BDNF and antibody-SCF suppressed the NSI-189-mediated rescue of cell viability against OGD (p > 0.05), further implicating the role of neurogenic factors in tandem with neurite outgrowth enhancement (Fig. 5) .
| DISCUSSION
The present findings support the use of oral NSI-189 at a wider therapeutic window of 6 hr post-stroke in enhancing host neurogenesis, possibly acting via upregulation of neurogenic factors, towards functional recovery in stroke. Both sets of in vivo and in FIGURE 1 NSI-189 promotes behavioral recovery in stroke. Stroke animals that received NSI-189 displayed significant amelioration of stroke-induced motor and neurological deficits as early as day 3 post-stroke, and continued to improve over the 24 weeks survival compared to vehicle-treated stroke animals. The observed behavioral recovery in NSI-189-treated stroke animals was noted in all monthly test time points, and in both EBST (A) and neurological examination (B)
vitro experiments indicated that targeting the secondary cell death of impaired neurogenesis may confer robust benefits against stroke.
The early behavioral effects of NSI-189 in MCAo stroke animals, starting at day 3 after drug initiation, highlight the robust effects of this small molecule, likely owing in part to its ability to penetrate the blood brain barrier (BBB) even before the stroke-induced BBB breakdown.
Equally notable is the continued behavioral improvement and maintained behavioral recovery over time (up to 24 weeks), even when NSI-189 was terminated at 12 weeks post-stroke. This sustained functional improvement suggests that the drug likely initiated a host brain repair mechanism that was able to continue the tissue remodeling process of the stroke brain in the absence of daily NSI-189 treatment.
That the brain remodels itself after stroke has been documented (Hermann et al., 2014; Tajiri et al., 2012; Watson et al., 2015; Zhang & Chopp, 2015) , but this host repair mechanism is not sufficient to account for sustained relevant stroke recovery (Doeppner et al., 2009; Hess & Borlongan, 2008a; Hu et al., 2013; Kuge et al., 2009 ).
Exogenous treatment, either pharmacologically or via stem cell transplantation, designed to enhance host brain regenerative process is needed to achieve clinically relevant functional outcomes in stroke shown in the present study to preferentially occur in the hippocampal areas and peri-infarct cortex undergoing secondary cell death as opposed to the striatal areas proximal to the primary stroke insulted region. Indeed, stroke appears to awaken quiescent stem cells in the brain, in both neurogeneic and non-neurogenic niches (Lindvall & Kokaia, 2015; Péron & Berninger, 2015) , and stimulation of these cells with neurogenic molecules, such as NSI-189, may facilitate host brain neurogenesis (Kreuzberg et al., 2010; Li, Yu, Mohamad, Genetta, & Wei, 2010; Osman, Porritt, Nilsson, & Kuhn, 2011) . Our observation that enhanced neurogenic activity was more prominent in the SGZ, remote from the principally stroke infarcted area, suggests that obliterating the secondary cell death as opposed to the principal stroke insult, may be more amenable to treatments targeting host repair mechanisms.
Our cell culture studies revealed that in concert with enhanced neurogenesis, NSI-189 also upregulated neurogenic factors. NSI-189 treatment reversed the OGD-triggered cell death in cultured hippocampal cells, coincident with increased Ki67 expression and MAP2 density, likely corresponding to an enhanced neurogenic activity. While the composition of our cell population represented 40% neurons and 60% astrocytes, the phenotypic expression of these cells may be considered as immature because the timing of cell harvest corresponds to gestation age day 16. Moreover, the hippocampus being the targeted donor brain region contains one of the most active neurogenic niches, the SGZ. Accordingly, it is highly likely that due to the young age and potent neurogenic tissue source of our neural cultures, there was a small subset of immature and proliferative cells that are Ki67 positive cells whose proliferative activity was enhanced by NSI-189. In tandem with such active neurogenesis, elevated Brill et al., 2009; Chapman et al., 2015; Lu, Jones, Snyder, & Tuszynski, 2003; Zhang et al., 2015) and neurogenesis following brain insults, including stroke (Kernie and Parent, 2010; Yamashita et al., 2006) . We (Hara et al., 2007; Morimoto et al., 2011; Tajiri et al., 2013) , and others, have shown the important contribution of neurogenic factors in stroke brain remodeling (Jablonska et al., 2016; Rosell et al., 2013; Seo et al., 2014; Venna, Xu, Doran, Patrizz, & McCullough, 2014) . Altogether, these results allude to host neurogenesis and its secreted neurogenic factors as key therapeutic targets of NSI-189 in affording behavioral and neurostructural benefits in stroke.
The recent entry of NSI-189 in the clinic as a treatment for major depression (ClinicalTrials.gov, 2016; Fava et al., 2015) , coupled with the present laboratory data demonstrating the therapeutic efficacy of this small molecule in an animal model of stroke, warrants a careful consideration of its application in ischemic stroke patients. Until now, the molecular mechanisms mediating the neurogenic effects of NSI-189 remain underexplored. The observed growth factor elevation and neurite outgrowth enhancement provide insights into optimizing the therapeutic benefits of NSI-189 in neurological disorders.
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